Cannabinoids and Chemotherapy-Induced Nausea: What the Clinical Evidence Supports

Cannabinoids may have a role in chemotherapy-induced nausea and vomiting (CINV), but the clinical evidence supports them mainly as an adjunct for refractory CINV—not as a replacement for standard antiemetic treatment or as routine first-line therapy.

By Cannible Editorial

2026-08-09

This article is general information and does not replace guidance from an oncology team.

The practical bottom line

For most patients receiving chemotherapy, cannabinoids should not be viewed as a substitute for guideline-concordant antiemetic care. The clinical guidance specifically describes possible benefit when cannabis or cannabinoids are added to an appropriate antiemetic regimen for refractory CINV, meaning nausea or vomiting that remains inadequately controlled. 1

Evidence for using cannabinoids as routine prophylaxis or first-line treatment is not strong in the era of modern combination antiemetics. A recent review found that most included studies were conducted before the 2000s, nearly half had some concern for bias, and there is scant evidence in the setting of triple- and quadruple-antiemetic regimens. 2

A newer THC:CBD study reported better secondary prevention of CINV when used as adjunctive therapy alongside modern antiemetics, but most participants were not receiving olanzapine. Further research is needed to establish safety and effectiveness alongside contemporary regimens that include olanzapine. 2

Approved cannabinoid medicines and their labeled use

Approved cannabinoid medicines are distinct from cannabis products generally. The evidence and guidance address several categories, including synthetic cannabinoids, herbal cannabis derivatives, single purified cannabinoids, combinations of cannabis ingredients, and full-spectrum cannabis. Results from one category should not automatically be assumed to apply to every cannabis product. 1

Dronabinol, marketed as Marinol, is labeled for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. That labeling means it is not presented as the initial antiemetic option when conventional treatment has not yet been tried or has worked adequately. 3

Nabilone, marketed as Cesamet, is also labeled for chemotherapy-associated nausea and vomiting in patients who have failed to respond adequately to conventional antiemetic treatments. Its label explicitly states that it is not intended to be used on an as-needed basis or as a first antiemetic product prescribed for a patient. 4

The nabilone label requires this restriction because a substantial proportion of treated patients may experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because nabilone can alter mental state, the label calls for close supervision, particularly during initial use and dose adjustments. 4

These labeled restrictions reinforce the broader clinical distinction: approved cannabinoid medicines may be considered after conventional antiemetic treatment has not provided adequate control, while cannabis or cannabinoid use should not displace standard antiemetic care. Any decision about whether an approved medicine is appropriate belongs with the oncology team. 1 3 4

What the clinical evidence shows

Older randomized comparisons found that cannabinoids were more effective than several older antiemetic medicines for complete control of nausea and vomiting. However, those studies evaluated treatments used before the current era of modern multi-drug antiemetic regimens, and the findings do not establish cannabinoids as superior to today’s standard first-line approach. 5 2

A later systematic review found oral cannabinoids more effective than placebo or the other studied treatments when nausea and vomiting were considered together, but found them equally effective to other treatments when nausea or vomiting were considered separately. The review also emphasized that the trials were limited in number, often compared cannabinoids with older regimens, and used inconsistent reporting. 6

The strongest current support is therefore narrower: cannabinoids may help selected patients whose CINV remains uncontrolled despite guideline-concordant antiemetic treatment, particularly when used as an add-on or later-line option. The relevant guideline characterizes the evidence base as limited and calls for more research. 1

Side effects and questions for the oncology team

Cannabinoids can cause effects that matter when choosing an antiemetic. In older trials, patients receiving cannabinoids experienced “high,” sedation or drowsiness, euphoria, dizziness, dysphoria or depression, hallucinations, paranoia, and arterial hypotension more often than comparison groups; withdrawals because of side effects were also more common. 5

For nabilone specifically, the labeling identifies potential mental-state effects and warns about abuse, misuse, and excessive use. It also notes increased substance-abuse risk in people with a personal or family history of substance abuse or mental illness. 4

Before using cannabis, a cannabis product, dronabinol, or nabilone during chemotherapy, discuss the plan with the oncology team. Useful questions include whether the nausea or vomiting is refractory, which standard antiemetic regimen is being used, whether a cannabinoid would be an adjunct rather than a replacement, and which mental-state or other adverse effects are especially concerning for that patient. 1 4

Cannabinoids and Chemotherapy-Induced Nausea: What the Clinical Evidence Supports

The practical bottom line

Approved cannabinoid medicines and their labeled use

What the clinical evidence shows

Side effects and questions for the oncology team

Sources